New activity is brewing for Staar Surgical ( (STAA) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
On August 4, 2025, STAAR Surgical Company entered into a merger agreement with Alcon Research, LLC, and Rascasse Merger Sub, Inc., a subsidiary of Alcon. According to the agreement, STAAR will merge with Rascasse Merger Sub, becoming a wholly owned subsidiary of Alcon. STAAR stockholders will receive $28.00 in cash per share, representing a 59% premium to the 90-day volume weighted average price of STAAR stock as of August 4, 2025. The merger, which has been unanimously approved by STAAR’s Board of Directors, is contingent upon stockholder approval at a special meeting scheduled for October 23, 2025. If completed, STAAR will cease to be publicly traded, impacting its stockholders and market presence.
The most recent analyst rating on (STAA) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
Staar Surgical’s overall stock score is primarily impacted by financial struggles, with declining revenues and negative margins being significant concerns. Technical analysis shows bullish momentum, but valuation remains weak due to negative profitability. The earnings call provides some optimism with strategic initiatives, but challenges in China and profitability issues weigh heavily.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical Company operates in the medical device industry, primarily focusing on the development, manufacturing, and marketing of implantable lenses for the eye. The company’s products are designed to improve vision and are used in refractive and cataract surgeries. STAAR Surgical is listed on NASDAQ under the symbol ‘STAA’.
Average Trading Volume: 1,574,210
Technical Sentiment Signal: Hold
Current Market Cap: $1.37B
Find detailed analytics on STAA stock on TipRanks’ Stock Analysis page.